

# Harbor-UCLA Medical Center

## January 1 - December 31, 2020 Cumulative Antimicrobial Susceptibility Report\*

Gram-Negative Organisms (Non-Urine Isolates)	No. of isolates tested	% Susceptible (number of isolates tested)										
		Beta-lactams						Fluoroquinolones		Aminoglycosides		Other
		Ampicillin	Ceftriaxone	Ceftazidime	Cefepime	Pip/tazo	Meropenem	Ciprofloxacin	Levofloxacin	Gentamicin	Amikacin	TMP-SMX
<i>Acinetobacter baumannii</i> complex	25**	-	12	68	68	72	76	76	76	80	-	72
<i>Citrobacter koseri</i>	32	-	97	97	NR	99	100	100	100	100	100	97
<i>E. coli</i>	414	39	81	90	NR	91	100	74	74	89	99	66
<i>Enterobacter cloacae</i> complex	119	-	85	89	100	86	99	99	99	100	100	93
<i>Klebsiella (Enterobacter) aerogenes</i>	94	-	63	64	100	64	99	97	96	100	100	100
<i>Klebsiella oxytoca</i>	36	-	89	94	NR	97	100	97	100	92	100	86
<i>Klebsiella pneumoniae</i>	206	-	80	81	NR	88	96	83	84	88	98	81
<i>Morganella morganii</i>	46	-	83	83	NR	93	98	83	85	76	100	65
<i>Proteus mirabilis</i>	160	78	94	100	NR	98	100	86	86	91	100	76
<i>Pseudomonas aeruginosa</i>	289	-	-	88	87	85	88	91	79	93	100	-
<i>Serratia marcescens</i>	78	-	95	99	NR	-	99	97	97	100	99	100
<i>Stenotrophomonas maltophilia</i>	63	-	-	-	-	-	-	-	91	-	-	97

\*Percent susceptible for each organism/antimicrobial combination was generated by including first isolate of that organism for a given patient.

\*\*Calculated from fewer than the standard 30 isolates

Abbreviations: % S, percent susceptible; No., number; NR, not reported; Pip/tazo, piperacillin/tazobactam; TMP-SMX, trimethoprim/sulfamethoxazole.

# Harbor-UCLA Medical Center

## January 1 - December 31, 2020 Cumulative Antimicrobial Susceptibility Report\*

### Urine Isolates ONLY

Gram-Negative Organisms	No. of isolates tested	% Susceptible (number of isolates tested)											
		Beta-lactams						FQ	Aminoglycosides		Others		
		Ampicillin	Cefazolin	Ceftriaxone	Ceftazidime	Cefepime	Pip/tazo	Meropenem	Ciprofloxacin	Gentamicin	Amikacin	TMP-SMX	Nitro
<i>Citrobacter koseri</i>	56	-	-	95	95	NR	98	100	100	100	100	98	91
<i>E. coli</i>	3514	46	86	89	93	NR	96	100	75	89	100	65	95
<i>Enterobacter cloacae</i> complex	99	-	-	74	76	97	78	100	97	99	100	90	36
<i>Klebsiella (Enterobacter) aerogenes</i>	75	-	-	71	71	100	71	99	95	100	100	96	8
<i>Klebsiella oxytoca</i>	45	-	-	93	93	NR	96	100	91	91	98	89	78
<i>Klebsiella pneumoniae</i>	600	-	84	85	89	NR	93	99	88	91	100	80	25
<i>Morganella morganii</i>	51	-	-	92	90	100	92	100	86	86	100	78	-
<i>Proteus mirabilis</i>	423	80	96	97	100	99	99	100	91	92	100	83	-
<i>Pseudomonas aeruginosa</i>	138	-	-	-	87	86	84	92	86	90	98	-	-
<i>Serratia marcescens</i>	30	-	-	87	100	NR	-	97	97	100	100	97	-
Gram-Positive Organisms		Penicillin	Ampicillin	Vancomycin	Nitro								
<i>Enterococcus faecalis</i>	445	99	100	98	100								
<i>Enterococcus faecium</i> (all)	73	18	19	34	21								
<i>Enterococcus faecium</i> (VRE)	48	0	4	0	9								

\*Percent susceptible for each organism/antimicrobial combination was generated by including first isolate of that organism for a given patient.

Abbreviations: % S, percent susceptible; No., number; NR, not reported; FQ, fluoroquinolone; Pip/tazo, piperacillin/tazobactam; TMP-SMX, trimethoprim/sulfamethoxazole; Nitro, nitrofurantoin; VRE, vancomycin-resistant enterococci.

# Harbor-UCLA Medical Center

## January 1 - December 31, 2020 Cumulative Antimicrobial Susceptibility Report\*

Gram-Positive Organisms (Non-Urine Isolates)	No. of isolates tested	% Susceptible (number of isolates tested)										
		Beta-lactams				Fluoroquinolones		Other				
		Penicillin	Ampicillin	Ceftriaxone	Oxacillin	Ciprofloxacin	Levofloxacin	Clindamycin	Linezolid	TMP-SMX	Tetracycline	Van
<i>Staphylococcus aureus</i> (all)	1169	13	-	-	65	66	66	77	100	96	90	100
MSSA	767	19	-	-	100	90	91	80	100	98	91	100
MRSA <sup>a</sup>	402	0	-	-	0 <sup>a</sup>	19	19	72	100	92	88	100
Coagulase-negative <i>Staphylococcus</i> (excluding <i>S. lugdunensis</i> )	148	19	-	-	45 <sup>a</sup>	65	66	58	100	-	79	100
Group B <i>Streptococcus</i> (GBS) <sup>b</sup>	32	100	100	-	-	-	-	.b	-	-	-	100
Viridans <i>Streptococcus</i>	45	81	-	87	-	-	-	-	-	-	-	100
<i>Enterococcus faecalis</i>	264	99	100	-	-	-	-	-	100	-	29	100
<i>Enterococcus faecium</i> (all)	53	30	34	-	-	-	-	-	100	-	32	43
<i>Enterococcus faecium</i> (VRE)	31	0	0	-	-	-	-	-	-	-	13	0

\*Percent susceptible for each organism/antimicrobial combination was generated by including first isolate of that organism for a given patient.

a. Oxacillin-resistant staphylococci are considered resistant to all currently available beta-lactam agents, except for newer cephalosporins with anti-MRSA activity (i.e. ceftaroline).

b. For GBS, penicillin is drug of choice and is a surrogate for ampicillin, amoxicillin, and cefazolin. For severe penicillin-allergic patients, clindamycin is not recommended without susceptibility testing, use alternate therapy.

Abbreviations: % S, percent susceptible; No., number; TMP-SMX, trimethoprim/sulfamethoxazole; Van, vancomycin; VRE, vancomycin-resistant enterococci.